Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues.

Yoo KH., Jang IK., Lee MW., Kim HE., Yang MS., Eom Y.

Laboratory Study on Chronic Inflammation, Immune Modulation, published in Cell Immunol (2009) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cell Immunol (2009)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
19608159
DOI
10.1016/j.cellimm.2009.06.010

Abstract (original English)

Mesenchymal stem cells (MSCs), which evoke only minimal immune reactivity, may have anti-inflammatory and immunomodulatory effects. In this study, we conducted a comparative analysis of the immunomodulatory properties of MSCs derived from adult human tissues including bone marrow (BM), adipose tissues (AT), umbilical cord blood (CB), and cord Wharton's jelly (WJ). Using a multiple cytokine detection assay, we showed that there were no significant differences in levels of secreted factors from non-stimulated MSCs. We compared the immunosuppressive effect of BM-MSCs, AT-MSCs, CB-MSCs, and WJ-MSCs on phytohemagglutinin-induced T-cell proliferation. AT-MSCs, CB-MSCs, and WJ-MSCs effectively suppressed mitogen-induced T-cell proliferation as effectively as did BM-MSCs. Levels of interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha secreted from activated T-cells increased over time, but these levels were significantly reduced when cocultured with each type of MSCs. In addition, the expression of hepatocyte growth factor, IL-10, transforming growth factor-beta(1), cyclooxygenase (COX)-1, and COX-2 were unchanged in MSCs treated with IFN-gamma and/or TNF-alpha, while indoleamine 2,3-dioxygenase (IDO) expression increased. IFN-gamma and/or TNF-alpha produced by activated T-cells were correlated with induction of IDO expression by MSCs, which, in turn, suppressed T-cell prolifer

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAntigens, CDBone Marrow CellsCell ProliferationCytokinesFetal BloodFlow CytometryHumansImmunoblottingMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research